Literature DB >> 32224439

The role of disease duration and severity on novel clinical subtypes of Parkinson disease.

Roberto Erro1, Marina Picillo2, Sara Scannapieco2, Sofia Cuoco2, Maria Teresa Pellecchia2, Paolo Barone2.   

Abstract

INTRODUCTION: One of the latest subtyping systems of Parkinson disease (PD) identifies motor severity, cognitive dysfunction, dysautonomia, and rapid eye movement behavior disorder as key features for phenotyping patients into three different subtypes (i.e., mild motor-predominant, diffuse-malignant and intermediate). Since PD subtypes are clinically most relevant if they are mutually exclusive and consistent over-time, we explored the impact of disease stage and duration on these novel subtypes.
METHODS: One-hundred-twenty-two consecutive patients, with a disease duration ranging from 0 to 20 years, were allocated as suggested into these three subtypes. The relationship between either disease duration or stage, as measured by the Hoehn and Yahr staging, and subtype allocation was explored.
RESULTS: Significant differences in subtype distribution were observed across patients stratified according to either disease duration or staging, with the diffuse-malignant subtypes increasing in prevalence as the disease advanced. Both disease duration and staging were independent predictors of subtype allocation.
CONCLUSIONS: These novel PD subtypes are significantly influenced by disease duration and staging, which might suggest that they do not represent mutually exclusive disease pathways. This should be taken into account when attempting correlations with putative biomarkers of disease progression.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clusters; Dementia; Non-motor symptoms; Progression; Staging

Year:  2020        PMID: 32224439     DOI: 10.1016/j.parkreldis.2020.03.013

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  3 in total

1.  Survey-based identification of design requirements and constraints for a wearable tremor suppression device.

Authors:  Yue Zhou; Devin Box; Kenneth G Hardy; Mary E Jenkins; Jayne Garland; Michael D Naish; Ana Luisa Trejos
Journal:  J Rehabil Assist Technol Eng       Date:  2022-05-07

2.  Clinical classification systems and long-term outcome in mid- and late-stage Parkinson's disease.

Authors:  Emil Ygland Rödström; Andreas Puschmann
Journal:  NPJ Parkinsons Dis       Date:  2021-08-02

3.  Natural history and patterns of treatment change in Parkinson's disease: A retrospective chart review.

Authors:  Prakash Navaratnam; Steve Arcona; Howard S Friedman; Matthew Leoni; Shajahan Shaik; Rahul Sasane
Journal:  Clin Park Relat Disord       Date:  2021-12-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.